Amgen is getting whacked after disappointing study results for its $14,000 heart drug (AMGN)

Shutterstock WASHINGTON (Reuters) – Amgen’s Repatha drug cut the risk of heart attacks and strokes by over 20 percent in patients with heart disease, demonstrating a clear clinical benefit beyond its ability to slash “bad” LDL cholesterol levels, data from a huge study known as Fourier showed on Friday. Results from the highly anticipated 27,564-patient […]